Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?
COVID-19
PI3K/AKT pathway
SARS-CoV-2
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
06
2021
accepted:
18
06
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Commentary on 'Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19' by Sun et al.
Identifiants
pubmed: 34345206
doi: 10.7150/ijbs.63969
pii: ijbsv17p2770
pmc: PMC8326129
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2770-2771Commentaires et corrections
Type : CommentOn
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The author has declared that no competing interest exists.
Références
Clin Cancer Res. 2020 Aug 1;26(15):3947-3957
pubmed: 32312891
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Mol Sci. 2021 May 02;22(9):
pubmed: 34063231
Cytokine. 2021 Aug;144:155593
pubmed: 34074585
Nat Med. 2006 Oct;12(10):1203-7
pubmed: 16964257
JAMA Oncol. 2021 Feb 1;7(2):271-278
pubmed: 33377972
Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99
pubmed: 25487801
Nat Rev Microbiol. 2021 Jul;19(7):425-441
pubmed: 33824495
Int J Biol Sci. 2021 Jun 11;17(9):2348-2355
pubmed: 34239361
Breast Care (Basel). 2016 Dec;11(6):398-404
pubmed: 28228706